

UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: SZNAIDMAN, Marcos L. Art Unit: 1628

Re: Application of: KIM, Myung-Hwa, et al.
Serial No.: 10/562,615
Filed: July 27, 2006
For: **TRICYCLIC DERIVATIVES OR
PHARMACEUTICALLY SALTS THEREOF, THEIR
PREPARATIONS AND PHARMACEUTICAL
COMPOSITIONS CONTAINING THEM**
Confirmation No.: 6138

SUPPLEMENTAL RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

September 21, 2011

Sir:

In addition to the response submitted on September 12, 2011 in response to the Office Action dated May 10, 2011, the following remarks and a Declaration under 37 C.F.R. § 1.132 are provided.

REMARKS

Reconsideration of the present application, as amended, is respectfully requested.

A. DECLARATION UNDER 37 C.F.R. § 1.132

As briefly mention in the response submitted on September 12, 2011, the compound of the instant claims, especially having fluoride, contains superior pharmacological efficacy and significantly reduced toxicity compared to the compound in the cited reference, Kim et al.

Tables 3-5 in the response of September 12, 2011 provides evidence where the compounds of the present invention provides unexpectedly and significantly improved efficacy compared to paclitaxel, doxorubicin, and Compound 6 of Kim et al. The non-obviousness of the present invention can also be supported by the reduced toxicity of the compounds of the present invention